Drug Discovery Investors

Discovery Americas is a leading private equity fund in the evolution of industries, transforming companies into profitable growth platforms. We were born in 2003 with the clear purpose of promoting Mexico through the transformation of its most basic industries. We have created eight investment vehicles, with which we have invested in 24 companies within the transport and logistics, education, financial services and health sectors.

MaRS Discovery District is Canada’s anchor innovation hub and North America’s largest urban innovation hub. It supports startups and scale-ups in health, climate, and AI sectors by providing commercialization support, connections to capital, and access to specialized lab and office spaces.

Social Discovery Ventures is the international umbrella brand for group of technology and software engineering companies which provide platforms for social discovery, personal development, and online entertainment. We invest into, develop and support a range of B2C internet projects and brands under the framework of social discovery. Some of those projects are online dating, the finding of travel companions, social games, language learning and practicing communities etc.

Discovery Nusantara Capital is the venture capital arm of Hangzhou Zhexin IT Co., Ltd, specializing in startup investments. It primarily invests in gaming companies located in Indonesia and Southeast Asia. Discovery Nusantara Capital was founded in 2016 and is based in Indonesia.

Discovery Park Ventures LLC is a venture capital firm specializing in start-ups and early stage fund of fund investing. It makes primary, secondary investments and co-investments in select portfolio companies. It invests in science, information technology, life-science, biotech, medical devices and consumer sectors. It invests in the US-based Venture Capital funds. Discovery Park Ventures LLC was founded in 2022 and is based in Seattle, Washington with an additional office in Stockholm, Sweden.

BeiGene is a global biotechnology company specializing in the discovery, development, and commercialization of innovative molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. Founded in 2010, the company has rapidly expanded its presence worldwide, with operations in the United States, China, and other international markets. BeiGene's mission is to improve the accessibility and affordability of cancer treatments through a science-first approach, focusing on producing high-quality therapies efficiently. The company has developed a robust oncology pipeline addressing a significant portion of global cancer incidences, conducting over 140 clinical trials with more than 20,000 patients. Notable achievements include receiving regulatory approvals in over 70 markets for three internally developed medicines and establishing a state-of-the-art biologics manufacturing facility in Hopewell, New Jersey, to expand production capabilities. This facility is expected to employ hundreds of workers and support the company's broader expansion strategy to deliver innovative medicines to a global patient population.

NMT Capital is a venture capital firm specializing in early venture, mid venture, and late venture investments. The firm primarily invests in information technology, medical technology, and life science companies with a focus on medical devices, diagnostics, advanced materials, equiptment, biotechnology, specialty pharmaceutical, life sciences, and drug discovery tools. It considers investments in the United States, Europe, the Middle East and Asia, especially in companies seeking either to expand outside their region or to attract companies into their region. The firm prefers to be the lead investor in its portfolio companies. NMT Capital was formerly known as Nexus Medical Partners. NMT Capital was founded in 2004 and is based in Norwell, Massachusetts with additional offices in Greenville, South Carolina and Luxembourg, Luxembourg.

ArchiMed SAS is a private equity and venture capital firm specializing investing in small and middle market, growth buyouts, acquisitions, small-cap and mid-cap companies. The firm seeks to invest in healthcare industries with focus on biopharmaceutical products & services, life science tools, biologic services, medical devices & technologies, diagnostics, healthcare IT and consumer health. In Biopharma firm prefers to invest in small and large molecules, APIs, generic, primary and specialty pharma, pharma delivery, veterinary, outsourcing services such as bioanalytical, drug discovery or formulation services, Consumer Health, In Vitro Diagnostics, CRO, CDMO, CLO or specialized consulting, in Healthcare IT firm prefers to invest in clinical or non-clinical solutions for care providers, care payer solutions, biopharma-related software, outsourcing services. In care provider firm prefers to invest in homecare, specialized care delivery, outsourcing services, in Medtech firm provider, the firm prefers to invest in implants, equipment, consumables, services, outsourcing in field such as cardiovascular, dental, drug delivery, infection control, neuro, ophtalmo, orthopaedics, general surgery, wound care, veterinary, in public safety firm prefers to invest in biocontrol, food safety, environmental and healthcare-related TIC, health at work, in Diagnostics it prefers to invest in including In Vitro (IVD) and Imaging, in Life Sciences the firm prefers to invest in including tools, equipment, consumables and services, whether for bioprocessing, research, in consumer health it prefers to invest in cosmetics, health supplements, aesthetics, wellness, selfcare and physio. It prefers to invest in Europe, France, Switzerland, North America, APAC and LATAM region. It prefers to invest between €5 million ($5.36 million) and €1,000 million ($1,100 million) in the companies with sales value between $6.22 million and $124.33 million. It prefers to take majority and minority stake in the companies. ArchiMed SAS was founded in 2014 and is based in Lyon, France with additional offices in Paris, France; New York, New York; Singapore, Singapore and Tokyo, Japan.

Boxer Capital, LLC, is a private biotechnology investment fund based in San Diego, California that invents and invests in new therapeutics across multiple indications in order to create value through improved patient care and outcomes. Founded in 2005, Boxer Capital invests in private and public companies representing the entire drug development lifecycle - from early-stage pre-clinical discovery assets to late-stage clinical and commercial stage companies. Through disciplined analysis, our research and investment team identify opportunities to invest throughout the business life-cycle - from long term positions with mature biotechnology companies that have strong leadership and high growth potential, to building new biotechnology companies from the ground up. Our expert team includes scientists and clinicians who have been at the forefront of research and discovery across multiple therapeutic indications, including cardiovascular health, oncology, and neurological disease. Several members of our team continue to practice medicine and have had the privilege of leading clinical development for multiple drugs that are treating patients today.

Amgen Ventures is a venture capital arm of Amgen Inc. specializing in direct investments in early stage, seed/startup, growth capital, mid venture, later stage, and emerging companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, bone health, nephrology, metabolic disorders, neuroscience, and cardiovascular therapeutics. In oncology, it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care, including mucositis and cachexia. In nephrology, the firm focuses on renal failure and hyperparathyroidism. For inflammation, the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders, it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology, the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in Thousand Oaks, California; with additional offices in San Francisco, California; Seattle, Washington; and Cambridge, Massachusetts.

V-Bio Ventures is a life science venture capital fund that co-creates startups and invests in early- to mid-stage companies. They focus on therapeutics, including drug discovery and development, leveraging a preferred relationship with the VIB research institute.

Bullnet Gestión, SGEIC, S.A. is a venture capital firm specializing in growth capital and development capital financing. The firm considers investments in early stages including series-A, seed/start-ups, early venture, and mid venture stages. The firm does not invest in internet related businesses including consumer internet projects and biotechnology (drug discovery, molecules and chemicals etc.), audiovisual content businesses (movies, animation series, videogames etc.). The firm does not interest in acquiring entire businesses or majority stake. It prefers to invest in disruptive groundbreaking technology with focus on proprietary breakthrough technologies and technology-oriented projects with a focus on healthcare technology, software, electronic systems, microelectronics, commerial services & supplies, electronics, photonics, medical devices, scientific innovation, materials or nanotechnology projects, semiconductors & equipments, interactive home entertainment, hardware, high value added services and IT arena or closely related areas. The firm primarily invests in Spanish private companies and Portugal but is open to investing abroad. It considers investments between €0.25 million ($0.26 million) and €10 million ($10.56 million) in its portfolio companies. The firm takes minority stakes. It seeks to co-invest in larger projects and with other funds (both national and international) and business angels. Bullnet Gestión, SGEIC, S.A., formerly known as Bullnet Gestión, SGECR, S.A., was founded in 2002 and is based in Pozuelo de Alarcón, Spain.

Pantomath Group is a private equity firm specializing in Seed Stage, Startup Stage, Growth Stage, Mid-Market, Pre-IPO, and IPO. The firm prefers to invest in Consumer Goods; Food Retail, Hypermarkets & Super Centers, Packaged Foods & Meats, Household Products, Personal Products, Agricultural Products, Auto Parts & Equipment, Automobile & Motorcycle Manufacturers, Consumer Electronics, Home Furnishings, Homebuilding, Household Appliances, Housewares & Specialties, Apparel, Accessories & Luxury Goods, Textiles, Education Services; Energy, Chemicals and Materials; Commodity Chemicals, Diversified Chemicals, Specialty Chemicals, Fertilizers & Agricultural Chemicals, Industrial Gases, Oil & Gas Drilling, Oil & Gas Equipment & Services, Gas Exploration & Production, Oil & Gas Storage & Transportation, Coal & Consumable Fuels, Renewable Energy, Construction Materials, Metal & Glass Containers, Diversified Metals & Mining, Gold, Forest Products, Paper Packaging; Industrial & Engineering; Aerospace & Defense, Building Products, Construction & Engineering, Electrical Components & Equipment, Industrial Machinery, Construction & Farm Machinery & Heavy Trucks, Data Processing Services, Diversified Support Services, Commercial Printing, Environmental & Facilities Services, Air Freight & Logistics, Marine Ports & Services, Highways & Railtracks, Trucking; Digital & Technology; Internet Software & Services, Data Processing & Outsourcing Services, IT Consulting & Other Services, Application & Software Development, Home Entertainment Systems, Electronic Components, Electronic Equipment & Instruments, Electronic Manufacturing Services, Technology Distributors, Office Electronics; Healthcare & Pharma; Health Care Equipment, Health Care Supplies, Lifesciences Tools & Services, Facilities, Distributors, Managed Healthcare, Drug Discovery & Management, Active Pharmaceutical Ingredient, Formulations, Biotechnology; Business Services; Human Resource & Employment Services, Business Process Outsourcing Services, Research & Consulting Services, Security & Alarm Services, Facility Management Services. The firm seeks to invest in India. It prefers a ticket size of INR 750 million ($9 million). Pantomath Group was founded in 2013 and is based in Mumbai, India, with offices across Maharashtra, Gujarat, Punjab, and West Bengal

Pfizer Ventures (PV), the venture capital arm of Pfizer Inc., was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer. PV seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’s pipeline and shape the future of our industry.With a $600M capital commitment from Pfizer for private investments in 2018, PV invests in private companies at all stages of development, with a strong focus on early stage opportunities. Other investments, including start-ups and spinouts, will also be considered. We actively work with our current portfolio companies throughout their growth cycles, contributing strategic guidance in addition to our capital and providing access to internal Pfizer expertise, whenever appropriate. While primarily U.S. focused, international investments may represent up to 20% of the portfolio. We have the ability to lead or join a syndicate of investors and will seek board representation commensurate with our investment.INVESTMENT STRATEGYPrimarily focused on potentially transformative therapeutics, with an emphasis on Pfizer's core therapeutic areas (Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines).Focus also includes neuroscience investments, following Pfizer's decision to continue advancing research in this critical area of unmet medical need through a venture capital strategy.Will also consider platform technologies, diagnostics, drug delivery, pharmaceutical services and other technologies that have the potential to transform drug discovery and development.KEY POINTSActive investor, working with management to develop product strategy and build shareholder value.Bring Pfizer pedigree and perspective to our portfolio companies, with the potential to utilize the network and expertise of Pfizer.Streamlined approval process for investment decisions.Potential for Pfizer business development relationship whenever appropriate.

Vanneck Limited is a private equity firm specializing in investments in bridge financing, buyouts, and venture capital. It does not invest in start-up, IPO's, or very early stage companies but invests in later stages of the companies. The firm will not invest in companies with annualized turnover of under £1 million ($2 million). It seeks to invest during early venture, mid venture, and late venture stages of the companies. The firm invests in all sectors with a major focus on technology but it does not prefer to invest in oil or mineral exploration, drug discovery, or property companies. The firm invests in companies based in United Kingdom and North America in US. It invests between £1 million ($2 million) and £7.5 million ($15 million). The firm seeks investments in private growth companies that are intending to list on AIM or another market or a trade sale within, typically 24 months of investment. It also invests in companies that are already listed and are seeking capital as part of a refinancing. The firm also seeks to invest in companies that require finance to build out the balance sheet and operations in order to ensure viability as a listed entity; to replace early stage investors or, in some circumstances, managers, who wish to achieve a partial sale of their investment before listing; to provide bridge finance in anticipation of a listing, especially when market public market conditions for IPO's are poor; and to finance an acquisition made in anticipation of a listing or trade sale. The firm can either act as a lead investor or as part of a syndicate. It typically invests by way of a convertible loan, but will sometimes invest in simple equity. Vanneck Limited was founded in June 6, 2005 and is based in London, United Kingdom with an additional office in San Francisco, California.

Alerion Ventures is an evergreen venture capital firm based in Charleston, South Carolina, specializing in early-stage investments in scalable startups. Established in 2014, the firm focuses on sectors such as business-to-business software, technology-enabled services, healthcare software and services, and energy-efficient technologies. Alerion Ventures seeks companies that are capital-efficient and targeting markets with substantial scale and return-on-investment potential. The firm avoids investments in consumer-facing companies, drug discovery, medical devices, energy production, and project finance opportunities. Alerion Ventures prefers to partner with other experienced venture investors and has a preference for companies headquartered in the Southeast United States.

Boulder Ventures is a venture capital firm specializing in early-stage investments in information technology and biotechnology companies across Colorado and the Mid-Atlantic region. Established in the 1980s, the firm has a rich history of supporting innovative startups, leveraging decades-long relationships with entrepreneurs and investors. Their investment strategy focuses on identifying companies with unique, technology-enabled products that serve large or growing markets, particularly in software, networking, data storage, drug discovery, and technology-enabled services. Boulder Ventures typically invests between $1 million and $2 million in a funding round, aiming to be the first professional investor in their portfolio companies and reserving capital to participate in multiple investment rounds. The firm has raised approximately $371.1 million across seven funds, with the most recent, Boulder Ventures VIII, closing at $58 million in November 2022. Their portfolio boasts 61 companies, 28 exits, and 10 IPOs, reflecting a strong track record in nurturing successful ventures.

Echelon Ventures is a venture capital firm specializing in early stage investments. However, it does not seek investments in start-up ventures. It considers investments in companies with a proprietary enabling technology in information tchnology, communications, and life sciences with a special focus on software and hardware technologies for network communications, drug discovery, medical devices, semiconductor manufacturing, alternative power, and technologies that improve manufacturing processes. However, the firm can consider other areas as well. The firm will consider investments in companies based in New England area. It will invest in companies seeking finance between $1 million and $5 million in equity capital. The firm also leads or participates in the follow-on rounds with the portfolio companies and can invest with other venture firms as well. It prefers to take a board seat in its portfolio companies. Echelon Ventures was founded in 2000 and is headquartered in Waltham, Massachusetts.

Skyline Ventures is a venture capital firm founded in 1997, specializing in early-stage investments in healthcare and life science companies. The firm focuses on areas such as small molecule and protein therapeutics, medical devices, diagnostics, and technologies that facilitate drug discovery and life science research. With approximately $800 million under management, Skyline Ventures typically invests between $10 million and $15 million initially, aiming for total investments of $15 million to $35 million over the life of each portfolio company. The firm seeks to lead or co-lead first or second institutional venture rounds and often takes a board seat to provide strategic guidance. Its investment approach is grounded in thorough evaluation of scientific principles, market potential, and management quality, reflecting a commitment to data-driven decision-making rather than speculative trends.

Solasta Ventures is a venture capital firm dedicated to investing in innovative companies that aim to advance the standard of care for diseases with unmet medical needs. Leveraging deep scientific expertise and an extensive network, the firm identifies promising therapeutics and discovery platforms with the potential to transform patients' lives worldwide. Established as a wholly-owned subsidiary of Aju IB Investment, a leading South Korean venture capital firm, Solasta Ventures operates with a team possessing over 30 years of combined experience in healthcare investments and drug development. ( The firm's investment focus includes therapeutics and technology that transform care for patients in U.S. and global markets, strong management teams capable of efficiently utilizing capital, and potential for partnerships with global pharmaceutical companies, including those in their South Korean network.

UpStart Ventures is headquartered in Salt Lake City, Utah. Our investment strategy represents a unique combination of idea generation, science discovery, seed stage investing, venture judgment and company management. Our first fund, UpStart Life Sciences Capital, L.P. invests primarily in seed and early-stage healthcare companies, based on breakthrough technologies from major research universities, centered around Utah and neighboring states. We invest in opportunities such as medical devices, drug delivery systems, and diagnostics, as well as longer range investments in biopharma products and platforms. Central to our strategy is the belief that significantly more value can be created from the formation and initial management of leading edge life science companies than from traditional venture capital investing in pre-existing companies, whether at early or later stages.

Domain Associates is a venture capital firm specializing in the healthcare sector, focusing on investments in biotechnology, pharmaceuticals, medical devices, and diagnostics. Established in 1985, the firm has a rich history of partnering with innovative companies to bring transformative healthcare solutions to market. Their investment philosophy centers on identifying and nurturing early-stage companies with promising technologies and strong management teams. Notable achievements include the successful commercialization of several portfolio companies and a track record of significant returns for their investors. Domain Associates differentiates itself through its deep industry expertise, extensive network, and hands-on approach to supporting portfolio companies. The firm's areas of focus encompass a broad spectrum of healthcare innovations, from drug discovery to medical device development. Geographically, Domain Associates primarily invests in North America, leveraging its strong presence and understanding of the regional healthcare landscape.

UCB Ventures S.A. is a venture capital arm of UCB Pharma S.A. specializing in early stage and startups investments. The firm seeks to invest in innovative therapeutics and technology platforms; novel therapeutics modalities and platforms/assets that address novel biology. The firm seeks to invest in drug discovery, development and operations; breakthrough innovations in next-generation cell and gene therapy, regenerative medicine, cell and tissue homeostasis, Oligo-based and synthetic biology, and RNA modulation. The firm seeks to invest in US and Europe. UCB Ventures S.A. was founded in 2017 and is based in Brussels, Belgium with additional offices in London, United Kingdom; and Boston, Massachusetts.

Viva BioInnovator is a venture capital arm of Viva Biotech Holdings, specializing in incubation, seed, start-up, and early stage investments. The firm typically invests in biotech companies across all indications and drug types, especially companies with innovative solutions for unmet medical needs cross multiple therapeutic areas. It seeks to invest in companies based in the United States and also companies globally. The firm prefers investing in companies which fully utilize VBI drug discovery services particularly in innovative spaces such as gene and cell therapy. It seeks to invest between USD 0.5 million to USD 5 million for each investment. The firm typically invests in firms with market potential 5 to 10 years in the future. Viva BioInnovator was founded in 2014 and is based in Shanghai, China.

Breslin Biotech AG is a private equity and venture capital arm of Breslin AG specializing in direct and fund of fund investments. Within direct investments, it focuses on investments in seed, start-up, early Venture, mid venture, late venture development and expansion, spinout, venture debt, incubation, distressed, mezzanine, later stage, mature, turnaround, emerging growth, recapitalization, PIPES, industry consolidation, bridge financing, restructuring/turnaround, management buyins, and management buyouts. Within the fund of fund investment, it prefers to invest in venture capital funds, turnaround/distressed debt funds and secondary investing-limited partners interest. It seeks to invest in cleantech, energy, chemicals, industrial biotech, service providers and contract research organizations, medical devices and healthcare, agriculture, and environmental products, services, and projects, and IT industries. The firm typically invests in all sectors of life sciences with an emphasis on biopharmaceuticals, therapeutics, and drug research, discovery, development, and delivery; technology platforms that enable pharmaceutical and biotech companies to improve or accelerate drug development like genomics, drug delivery, and bioinformatics; and diagnostics like medicine, environment, food, human-kind sector, which includes areas related to social impact, technology, and quality of life. The firm primarily invests in companies based in United States, Asia, and Europe with a focus on Germany, Switzerland, and Austria. It invests between $0.5 million and $5 million and can make higher investments with involvement of some financial players. The firm takes a board seat in its portfolio companies. The firm invests through its personal capital. Breslin Biotech AG was founded in 1997 and is headquartered in Zurich, Switzerland with additional office at San Francisco, United States of America, and London, United Kingdom.